

1 LATHAM & WATKINS LLP
Katherine A. Lauer (Bar No. 138010)
2 *katherine.lauer@lw.com*
Jason M. Ohta (Bar No. 211107)
3 *jason.ohta@lw.com*
Amy E. Hargreaves (Bar No. 266255)
4 *amy.hargreaves@lw.com*
12670 High Bluff Drive
5 San Diego, CA 92130
Telephone: (858) 523-5400
6 Facsimile: (858) 523-5450

7 Steven M. Bauer (Bar No. 135067)
steven.bauer@lw.com
8 505 Montgomery Street, Suite 2000
San Francisco, CA 94111
9 Telephone: (415) 391-0600
Facsimile: (415) 395-8095

10 *Attorneys for Defendants Sutter Health and*
11 *Palo Alto Medical Foundation*

12 UNITED STATES DISTRICT COURT
13 NORTHERN DISTRICT OF CALIFORNIA
14 SAN FRANCISCO DIVISION

15 UNITED STATES OF AMERICA *ex rel.*
16 KATHY ORMSBY,

17 Plaintiff,

18 v.

19 SUTTER HEALTH and PALO ALTO
20 MEDICAL FOUNDATION,

21 Defendants.
22
23
24
25
26
27
28

Case No. 3:15-cv-01062-LB

**DEFENDANTS' REPLY IN SUPPORT
OF MOTION TO DISMISS RELATOR'S
FIRST AMENDED COMPLAINT**

Date: October 24, 2019

Time: 9:30 a.m.

Courtroom: Courtroom C, 15th Floor

Hon. Laurel Beeler

TABLE OF CONTENTS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

	Page
I. INTRODUCTION	1
II. DISCUSSION.....	2
A. Relator May Not Pursue Claims Beyond the Government’s Intervention.....	2
1. When The Government Intervenes, It “Take[s] Over” The Entire Action.....	2
2. There Is No “Partial Intervention” In This Circuit Or In This Case.....	4
3. The Government Fully Intervened In This Action	6
B. The Amended Complaint Fails The Rule 9(b) Particularity Requirement.....	10
1. Relator Fails to Allege a False Claim or Particular Details of a Scheme to Submit False Claims at the Non-PAMF Affiliates	10
2. A “Collective Fraud” Theory Does Not Relieve Relator of Complying with Rule 9(b)	13
3. Relator’s Remaining Arguments Fail	14
III. CONCLUSION.....	15

TABLE OF AUTHORITIES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Page(s)

CASES

Ebeid ex rel. United States v. Lunwitz,
616 F.3d 993 (9th Cir. 2010)10

Eclectic Props. East, LLC v. Marcus & Millichap Co.,
751 F.3d 990 (9th Cir. 2014)15

Foglia v. Renal Ventures Mgmt., LLC,
754 F.3d 153 (3d Cir. 2014).....12

United States ex rel. Bennett v. Biotronik, Inc.,
876 F.3d 1011 (9th Cir. 2017)2, 3

United States ex rel. Brooks v. Stevens-Henager College, Inc.,
359 F. Supp. 3d 1088 (D. Utah 2019).....6

United States ex rel. Dresser v. Qualium Corp.,
2016 WL 3880763 (N.D. Cal. July 18, 2016).....7

United States ex rel. Duxbury v. Ortho Biotech Prods., L.P.,
579 F.3d 13 (1st Cir. 2009).....11

United States ex rel. Edman v. Ma Labs., Inc.,
2018 WL 6016148 (C.D. Cal. May 3, 2018)10

United States ex rel. Feldman v. City of New York,
808 F. Supp. 2d 641 (S.D.N.Y. 2011).....7

United States ex rel. Integra Med Analytics, LLC v. Baylor Scott & White Health,
2019 WL 3713756 (W.D. Tex. Aug. 5, 2019).....13, 15

United States ex rel. Merena v. SmithKline Beecham Corp.,
205 F.3d 97 (3d Cir. 2000).....5

United States ex rel. Raggio v. Jacintoport Int’l, LLC,
2013 WL 2462109 (D.D.C. June 7, 2013).....8

United States ex rel. Silingo v. Wellpoint, Inc.,
904 F.3d 667 (9th Cir. 2018)13, 14

United States ex rel. Stillwell v. Hughes Helicopters, Inc.,
714 F. Supp. 1084 (C.D. Cal. 1989)2

United States ex rel. Swoben v. United Healthcare Ins. Co.,
848 F.3d 1161 (9th Cir. 2016)12, 14

1 *United States v. Mount Sinai Hosp.*,
 2 2015 WL 7076092 (S.D.N.Y. Nov. 9, 2015).....15

3 *United States v. Public Warehousing Co. K.S.C.*,
 4 242 F. Supp. 3d 1351 (N.D. Ga. 2017).....6

5 **STATUTES**

6 31 U.S.C.
 7 § 3729(a)(1)(G).....14
 8 § 3730.....3
 9 § 3730(a).....3
 10 § 3730(b).....2, 3
 11 § 3730(b)(1).....3
 12 § 3730(b)(4)(B).....2
 13 § 3730(c)(1).....2
 14 § 3730(c)(2)(A).....3
 15 § 3730(c)(3).....2
 16 § 3731(c).....2, 9
 17 § 3731(e).....3
 18 § 3732(b).....3

19 **RULES**

20 Fed. R. Civ. P. 9(b)..... *passim*

21 **TREATISES**

22 Boese, *Civil False Claims and Qui Tam Actions*, § 4.05[B].....2

23 **REGULATIONS**

24 72 Fed. Reg. 47130, 47180 (Aug. 22, 2007).....15

25
26
27
28

1 **I. INTRODUCTION**

2 Relator seeks to expand this action to include practices at several institutions not
3 mentioned at all in the original sealed Complaint or in the government’s Complaint-in-
4 Intervention. No person reading the original Complaint, however, could reasonably conclude
5 that it contained particularized allegations of fraud at institutions other than the Palo Alto
6 Medical Foundation (PAMF). Certainly, the government understood the allegations to be about
7 PAMF only. It announced its intervention in the sealed Complaint without limitation and
8 followed up with a Complaint with allegations only concerning PAMF. The Relator understood
9 this as well, as the Complaint contained no specific allegation about any activity outside of
10 PAMF—and the Amended Complaint concedes that all other allegations are only on information
11 and belief. Moreover, the Amended Complaint is the first time the names of other Sutter
12 facilities are mentioned at all—and just in boilerplate, identification allegations. Likewise,
13 Sutter understood the Complaint concerned PAMF, knowing that PAMF was the only facility at
14 which Relator worked. Original Compl. (ECF No. 1) ¶ 11; Am. Compl. (ECF No. 52) ¶ 8.

15 This should lead to the dismissal of Relator’s Amended Complaint for three reasons:

16 First, when the government intervened in the sealed Complaint, it intervened in the entire
17 action. The result, under the False Claims Act’s plain text and the Ninth Circuit’s clear
18 precedent, is that the government has taken over the action entirely. The Relator is not
19 authorized to expand this case beyond the allegations of the Complaint-in-Intervention.

20 Second, the partial intervention doctrine—judicially created and not endorsed in this
21 Circuit—cannot apply, because the government’s intervention was as broad as the sealed
22 Complaint and it did not decline to intervene in any way. The Complaint-in-Intervention
23 contains the same causes of action against the same defendants. This is not a “magic words”
24 trap; it is a common-sense interpretation of what actually happened.

25 Third, the Amended Complaint does not come close to the level of particularized fraud
26 allegations that Rule 9(b) requires. Vague assertions about general policies at institutions where
27 Relator did not work, or a “Sutter-wide” push to raise risk adjustment scores (which is not itself
28 inappropriate), are many steps removed from particularized allegations of fraud at other facilities

1 that were not even mentioned until the Amended Complaint. And the so-called “collective
2 allegations” theory does not create a life-ring saving Relator from having to make particularized
3 allegations going to the core elements of her claims.

4 The Court should dismiss Relator’s Amended Complaint without leave to amend.

5 **II. DISCUSSION**

6 **A. Relator May Not Pursue Claims Beyond the Government’s Intervention**

7 **1. When The Government Intervenes, It “Take[s] Over” The Entire 8 Action**

9 The words in the statute are clear and direct. The False Claims Act permits a relator to
10 bring “a civil action” on behalf of the government for violation of the statute. 31 U.S.C.
11 § 3730(b). Once the government intervenes in the suit, though, it “take[s] over the action.” *Id.*
12 § 3730(b)(4)(B). At that point, the statute’s plain language directs that the government “shall
13 have the primary responsibility for prosecuting the action,” *id.* § 3730(c)(1), including authority
14 to “file its own complaint or amend the complaint of [the relator] to clarify or add detail to the
15 claims in which the Government is intervening and to add any additional claims,” *id.* § 3731(c).
16 Only when “the Government elects not to proceed with the action” does the relator have “the
17 right to conduct the action.” *Id.* § 3730(c)(3).

18 Unsurprisingly, case law in the Ninth Circuit follows the plain language of the statute.
19 For example, “[t]he statute does not state that the Government may intervene in part of the action
20 or as to certain counts or certain claims for relief.” *United States ex rel. Bennett v. Biotronik,*
21 *Inc.*, 876 F.3d 1011, 1020 (9th Cir. 2017). Congress “carefully crafted” the amendments to the
22 FCA to enable the government to “take control of the course of the litigation.” *United States ex*
23 *rel. Stillwell v. Hughes Helicopters, Inc.*, 714 F. Supp. 1084, 1090 (C.D. Cal. 1989). And the
24 leading False Claims Act treatise agrees: “if the government elects to intervene, Sections 3730(b)
25 and (c) clearly provide that the government controls the action.” Boese, *Civil False Claims and*
26 *Qui Tam Actions*, § 4.05[B].

27 Relator acknowledges this authority only in a footnote, and claims that it is not binding
28 here because *Bennett* involved a different implication of the government’s takeover. Opp’n at

1 16; *id.* n.16. But that is beside the point: The Ninth Circuit’s decision in *Bennett* rested on its
2 interpretation of the key provision here—Section 3730(b)(2), the provision of the False Claims
3 Act that “describes the process of the Government’s intervention in a *qui tam* action.” *Bennett*,
4 876 F.3d at 1020. Citing that provision, the Ninth Circuit observed that the government may
5 “intervene and proceed with *the action*,” (emphasis added), and indicated that such intervention
6 constitutes a takeover of the action. *Id.* Ninth Circuit precedent is crystal clear on this point.

7 Relator seeks to avoid this result by arguing that “action” does not really mean action,
8 and that, one supposes, Congress meant to say “claim” at every turn. Read closely, the
9 provisions that Relator cites do not support the argument at all. Section 3730(h)(1) provides
10 protection from retaliation for lawful acts by an employee “in furtherance of *an action* under this
11 section.” “[T]his section” refers to “*civil actions* for false claims,” not to single claims for relief.
12 31 U.S.C. § 3730. Section 3731(e) estops a defendant, after final judgment in a related criminal
13 proceeding, from denying the essential elements of an offense in “any action” brought under
14 Sections 3730(a) or (b). Both Sections 3730(a) and (b) refer to “a civil action.” And Section
15 3732(b) provides for federal jurisdiction over any action brought under state law “if the action
16 arises from the same transaction or occurrence as an action brought under section 3730,” which,
17 again, refers to “civil actions.” These provisions support the common-sense conclusion that
18 “action” means “civil action,” not separate claims.

19 Relator also argues that that if “take over the action” means the government takes over
20 the entire action, then there would be some kind of conflict with the government’s right to
21 consent to dismissing a relator’s claims, Section 3730(b)(1), and the relator’s right to object to a
22 dismissal, Section 3730(c)(2)(A). Opp’n at 15. That is wrong. Both provisions just show the
23 government’s authority over the action. The first provision concerns when a relator seeks
24 dismissal before government intervention—clarifying that the government can stop this if it
25 chooses. The second provision allows a relator to object to a dismissal, but dismissal of the
26 action is still the government’s decision. There is nothing in these provisions supporting the
27 argument that “action” does not mean “action.”

28

1 In sum, the government intervened in the action with a Complaint alleging the same
2 claims against the same defendants as the under-seal Complaint. Relator cannot expand the
3 action. The issue is straightforward and the Court’s analysis should begin and end here.

4 **2. There Is No “Partial Intervention” In This Circuit Or In This Case**

5 To try to expand this action, Relator argues the government only “partially intervened,”
6 and urges this Court to accept partial intervention as an unwritten exception to the direct
7 language of the False Claims Act discussed above. This argument would require the Court to
8 accept two incorrect premises: (1) that the original Complaint made particularized allegations
9 concerning institutions where Relator did not work, and (2) that the idea of partial intervention
10 should be adopted in this Circuit.

11 **a. The Sealed Complaint**

12 The first step in assessing Relator’s argument is to focus on the sealed Complaint.
13 Because that Complaint does not make legally sufficient allegations of fraud at the four
14 institutions Relator seeks to add to this case, there is no way to interpret the government’s
15 intervention as a decision not to intervene in allegations against the four unnamed institutions.

16 The original Complaint asserts three claims for violation of the False Claims Act against
17 “Defendant Sutter” and “Defendant PAMF” based on allegations that Relator learned “first-
18 hand” as a PAMF employee. Original Compl. ¶¶ 5-6. In fact, the original Complaint never
19 identifies any specific Sutter affiliate other than PAMF, or any official at a Sutter affiliate other
20 than PAMF. On the few occasions where the original Complaint does mention Sutter’s “other
21 affiliates”—in passing, collective references—it does so as background or in an attempt to
22 bolster the suggestion of alleged fraud at PAMF, not to state claims against other unidentified
23 affiliates. *See id.* ¶¶ 5, 9, 90, 114, 119. On a plain reading of this Complaint, Relator cannot
24 plausibly argue that she asserted “claims” against any non-PAMF affiliate. *Id.* ¶¶ 124-26
25 (asserting claims against “Sutter and PAMF”); *id.* ¶ 131 (same); *id.* ¶ 139 (same).

26 The government read it the same way. In its notice of intervention, the government
27 explained that it was intervening in the action and that it “intend[ed] to file its own complaint
28 against Defendants Sutter Health and Palo Alto Medical Foundation . . . and potentially other

1 affiliated entities.” ECF No. 26, ¶¶ 1-2. It then filed a Complaint-in-Intervention against the
2 same defendants asserting the same claims (and three additional ones) as those alleged in
3 Relator’s original Complaint. Indeed, the government’s Complaint largely mirrors Relator’s
4 original Complaint—to include using some of the same alleged examples of false claims at
5 PAMF. Compare Original Compl. ¶ 117(a)-(e) with Govt. Compl. ¶ 133(a)-(i). And, like
6 Relator’s original Complaint, the government’s does not identify any specific Sutter affiliate
7 other than PAMF.

8 Relator’s Amended Complaint suggests the same conclusion. In her new Complaint,
9 Relator identifies Sutter’s other affiliates by name, Amend. Compl. ¶ 11, mentions an audit and
10 alleged training issues at Sutter Gould, *id.* ¶¶ 100, 107, and asserts that fraud “did not occur just
11 at PAMF but throughout its network of affiliates,” *id.* ¶ 6. But all of this just reinforces what
12 was not in Relator’s original, sealed Complaint. Relator’s original Complaint did not identify
13 any Sutter affiliate other than PAMF, and certainly did not make the (conclusory) allegations
14 regarding Sutter Gould that Relator makes in her Amended Complaint. Those allegations were
15 added only after the government and Sutter settled a dispute concerning the other institutions.
16 Relator’s attempt to expand her claims after the settlement confirms that her original Complaint
17 was limited to Sutter and PAMF—it did not assert claims of fraud at the non-PAMF affiliates.

18 b. There Is No “Partial Intervention”

19 The next requirement for Relator’s argument is to accept the idea of a partial intervention
20 doctrine and interpret its scope. Relator’s authority for this argument is a collection of largely
21 out-of-circuit district court cases. The only Circuit-level authority Relator discusses is *United*
22 *States ex rel. Merena v. SmithKline Beecham Corp.*, 205 F.3d 97, 101 (3d Cir. 2000), to argue
23 that partial intervention is appropriate because interpreting “take over the action” to mean entire
24 action would be “inconsistent with the multi-claim nature of FCA actions.” Opp’n at 15-16.
25 What the *Merena* case was primarily about, however, is whether the government may prevent a
26 relator from receiving a share of the proceeds attributable to a claim that is subject to dismissal
27 under the public disclosure bar. It does not stand for the proposition that a relator can expand the
28 scope of a case beyond the government’s intervention.

1 Nearly all of Relator’s other citations are out-of-circuit, lower court cases that focus only
 2 on the question whether a relator may proceed with a separate claim when the government
 3 specifically declined to intervene on that claim. *See, e.g., United States v. Public Warehousing*
 4 *Co. K.S.C.*, 242 F. Supp. 3d 1351, 1357-58 (N.D. Ga. 2017) (permitting relator to pursue certain
 5 claims after intervention when the government did not intervene on those claims). That is not
 6 the case here, and so this and Relator’s other cases are inapplicable.

7 Nor should Relator’s cases be taken to mean that all trial courts outside this Circuit
 8 endorse partial intervention. In *Brooks*, for example, Judge Parrish concluded, after an
 9 exhaustive analysis of intervention doctrine, that “[t]he right to continue as a party to the action
 10 is more limited than the right to conduct the action, and it does not encompass the right to add
 11 defendants and claims to the action.” *United States ex rel. Brooks v. Stevens-Henager College,*
 12 *Inc.*, 359 F. Supp. 3d 1088, 1124-25 (D. Utah 2019).

13 Relator attempts to distinguish *Brooks* by arguing that “*Brooks* concerned a relator who
 14 added new claims and new defendants *after* the government had already intervened.” Opp’n at
 15 14. But that is precisely what Relator is attempting to do here: add new claims involving alleged
 16 fraud at Sutter’s non-PAMF affiliates after the government has already intervened. Contrary to
 17 Relator’s arguments, *Brooks*, by prohibiting a relator from expanding the scope of her claims
 18 after the government took over the action, controls the circumstances presented here.¹

19 3. The Government Fully Intervened In This Action

20 Relator’s case authority for her argument that she has standing to pursue different claims
 21 alongside the government generally involve the government’s decision *not* to intervene in certain
 22 claims originally asserted by a relator. They do not stand for the proposition that Relator
 23 suggests here: that once the government intervenes, a relator has *carte blanche* to pursue her
 24 own complaint by adding in new claims that the government could have added, but did not.

25
 26
 27 ¹ Curiously, Relator claims that *Brooks* is Defendants’ “sole support” for the principle that a
 28 relator may not pursue additional claims after the government has taken over a False Claims Act
 case. Opp’n at 11. Of course it isn’t. As is clear from Defendants’ Motion to Dismiss, MTD at
 3-4, Defendants’ primary support for their argument is the text of the statute. And *Brooks* itself
 cites the Ninth Circuit’s decision in *Bennett*, which of course, Defendants also rely on.

1 Relator leans heavily on *United States ex rel. Dresser v. Qualium Corp.*, 2016 WL
2 3880763 (N.D. Cal. July 18, 2016), but even applying the *Dresser* analysis, Relator’s case should
3 be dismissed. In *Dresser*, a relator asserted theories of Medicare fraud in connection with sleep
4 tests and sleep disorder-related devices. The government intervened in part, after which the
5 relator continued to pursue claims alleging a different scheme to violate Medicare. The court
6 permitted her to proceed “as to the claims that [she] is pursuing on her own.” *Id.* at *10.

7 Relator contends that *Dresser* shows that the government need not use “magic words” to
8 identify the scope of its intervention before a relator can pursue separate claims. Opp’n at 13.
9 But *Dresser* does not stand for that proposition. In fact, in *Dresser*, the government explicitly
10 stated that it was “interven[ing] with respect to allegations that Defendants submitted claims for
11 payment in violation of Medicare rules and regulations for services performed at unapproved
12 locations; for services performed by unqualified or unlicensed personnel; and for durable
13 medical equipment supplied to Medicare beneficiaries.” *Dresser*, No. 12-cv-01745 (N.D. Cal.
14 2015), ECF No. 15. And it said just as explicitly that it “decline[d] to intervene as to any
15 allegations in the [relator’s] Complaint that are not related to the [aforementioned] allegations.”
16 *Id.* The relator then filed an amended complaint based on schemes that the relator alleged in her
17 original complaint, but as to which the government *declined to intervene*. It was on this basis
18 that the relator in *Dresser* was allowed to proceed.

19 Here, however, when the government intervened, it filed a Complaint-in-Intervention
20 against the same defendants asserting the same claims as those alleged in Relator’s original
21 Complaint. The government did not, as it did in *Dresser*, carve out claims as “non-intervened.”

22 There are many examples of courts dismissing intervened actions where the
23 government’s intervention covers the relator’s original complaint. For example, in *United States*
24 *ex rel. Feldman v. City of New York*, 808 F. Supp. 2d 641, 648-49 (S.D.N.Y. 2011), the court
25 held that a relator’s amended complaint was “superseded in its entirety” by the government’s
26 complaint where the government asserted “the same causes of action under the FCA as [the
27 relator]” and where the two complaints were “predicated on nearly identical factual allegations
28 of wrongdoing.” Other cases follow the same principle—a principle that applies with equal

1 force here. *See, e.g., United States ex rel. Raggio v. Jacintoport Int'l, LLC*, 2013 WL 2462109,
2 at *2 (D.D.C. June 7, 2013) (dismissing relator's amended complaint where the "amended claims
3 [were] identical to the Government's Complaint").

4 Relator argues that she mentioned "system-wide failure at Sutter" in her original
5 Complaint, and contends that the government did not intervene as to that aspect of her suit.
6 Opp'n at 9. But the original Complaint referred to supposed "system-wide" fraud only in
7 passing, as background to Relator's claim to have first-hand knowledge of fraud at PAMF. That
8 much is clear from the fact that the original Complaint names Sutter and PAMF and sought to
9 hold them *both* liable for all of the alleged fraud—something that makes sense only if all of the
10 alleged fraud on which the claims were based concerned activities at PAMF, and makes no sense
11 if the alleged fraud occurred elsewhere (because not even Relator can claim that there would be
12 any basis for holding PAMF liable for claims submitted by other affiliates). *See, e.g., Original*
13 *Compl.* ¶¶ 124-26 (asserting that "*Sutter* and *PAMF* are liable under the False Claims Act").

14 Finally, the timing here is revealing. Only *after* the government filed its Complaint—and
15 Relator learned that the government had separately reached a settlement with Sutter concerning
16 alleged overpayments at other affiliates—did Relator seek to expand the scope of her claims so
17 that they would include submissions at those other affiliates as well. The False Claims Act does
18 not allow a Relator to add in such additional claims after the fact. To hold otherwise would
19 allow relators to manufacture a new complaint to try to secure recoveries that the government
20 itself obtains through alternative means, such as the settlement that it reached here—which
21 Relator no doubt intends to claim she should share in.

22 Relator's other arguments for why the government's intervention was only "partial" are
23 also wrong. Relator contends that partial intervention is shown by the fact that the government's
24 Complaint "is silent about the Sutter-wide fraud and the misconduct Relator alleges occurred at
25 Sutter's other affiliates." Opp'n at 10. But the government's Complaint repeats nearly all of the
26 references to alleged Sutter-wide coding failures that Relator made in her original Complaint.
27 *See Govt. Compl.* ¶¶ 58, 68, 78, 89. And the government makes these allegations for the same
28 purpose that Relator did in her original Complaint: to bolster claims for relief against Sutter and

1 PAMF. That Relator is arguing that these allegations by the government constitute “silence”
2 regarding fraud at Sutter’s other affiliates just makes it all the more obvious that her original
3 Complaint did not assert claims involving the other Sutter affiliates, either.

4 Relator next points to the government’s notice of intervention as supporting her view that
5 the government only “partially” intervened here. That notice reads, “The United States intends
6 to file its own complaint against Defendants Sutter Health and Palo Alto Medical Foundation . . .
7 and potentially other affiliated entities.” ECF No. 26. Relator argues that because the
8 government did not file its own Complaint against “other affiliated entities,” then it did not
9 intervene as to Sutter’s non-PAMF affiliates. Opp’n at 9.

10 Here, again, Relator’s argument is self-defeating. Relator is correct that the
11 government’s Complaint did not assert claims against Sutter’s non-PAMF affiliates. *But neither*
12 *did Relator’s original Complaint.* The government could not decline to intervene as to claims
13 never asserted in the original Complaint. Nor could it decline to intervene against defendants not
14 named in Relator’s original Complaint. Under these circumstances, the government’s statement
15 that it might bring claims against “other affiliated entities” simply reflects its discretion under
16 Section 3731(c) “to add any additional claims with respect to which the Government contends it
17 is entitled to relief.” The fact that the government *could* have expanded the action in this way
18 does not undermine its full intervention in Relator’s original Complaint.

19 Finally, Relator invokes the government’s \$30 million settlement agreement with Sutter
20 and Sutter’s non-PAMF affiliates as support for the argument that the government was not
21 intervening against these other affiliates. Specifically, Relator points out that under paragraph 3
22 of the settlement, the government reserved the right to pursue a variety of claims, including
23 under the False Claims Act, which “would be nonsensical and extraneous” if the government had
24 fully intervened. Opp’n at 10. But that argument proceeds from a false premise: Relator never
25 asserted claims against Sutter’s non-PAMF affiliates, so any reservation of rights as to those
26 affiliates has no bearing on the government’s full intervention in this action. Here, the
27 government intervened in the same claims for relief against the same defendants outlined in
28

1 Relator’s original Complaint. Whatever the possible implications of the settlement’s reservation
2 of rights, it does not undermine the totality of the government’s intervention here.

3 **B. The Amended Complaint Fails The Rule 9(b) Particularity Requirement**

4 Dismissal is also appropriate for Relator’s failure to satisfy Rule 9(b). “An actual false
5 claim is the sine qua non of an FCA violation.” *United States ex rel. Edman v. Ma Labs., Inc.*,
6 2018 WL 6016148 at *3 (C.D. Cal. May 3, 2018). Under Rule 9(b)’s heightened pleading
7 standard, a relator must allege a specific false claim or set forth “*particular* details of a scheme to
8 submit false claims paired with reliable indicia that lead to a strong inference that claims were
9 actually submitted.” *Ebeid ex rel. United States v. Lunwitz*, 616 F.3d 993, 998-99 (9th Cir. 2010)
10 (emphasis added).

11 Relator’s Amended Complaint concedes that she cannot make specific allegations about
12 institutions other than PAMF. It states: “Relator – upon knowledge with respect to her own acts
13 and those she personally witnessed, and upon information and belief with respect to all other
14 matters – maintains her allegations of a Sutter-wide fraud.” Am. Compl. at 1:15-18. It should
15 not be unexpected that Relator cannot make specific allegations of fraud outside of PAMF. She
16 only worked at PAMF.

17 **1. Relator Fails to Allege a False Claim or Particular Details of a Scheme**
18 **to Submit False Claims at the Non-PAMF Affiliates**

19 As discussed above, Relator’s sole justification for proceeding with her own Complaint is
20 that “Sutter’s fraud did not occur just at PAMF *but throughout its network of affiliates* as Relator
21 witnessed first-hand.” Am. Compl. ¶ 6. But Relator’s allegations about activities outside of her
22 experience at PAMF are just boilerplate claims of “Sutter-wide” policies, with no detail about
23 whether those policies were implemented at each institution, what specific affects they had, and
24 whether this led to any particular false claim. Every allegation outside of PAMF relies on this
25 boilerplate, information-and-belief pleading, such as: (1) a “Sutter-wide” effort to increase risk
26 adjustment scores, *id.* ¶¶ 64, 68, 70, 73, 76, 78; (2) a lack of “Sutter-wide” training on coding, *id.*
27 ¶¶ 109-111, 113; (3) inaccurate coding “Sutter-wide,” *id.* ¶ 91; (4) audit failures “across Sutter’s
28 affiliates,” *id.* ¶¶ 98-99; and (5) Sutter’s unwillingness to expand audits “Sutter-wide,” *id.*

¶¶ 107, 120. But none of these allegations, or any of the other “Sutter-wide” allegations that Relator highlights in her opposition (at 21), constitute “particularized supporting detail” regarding a scheme to submit false claims at Sutter East Bay Medical Foundation, Sutter Pacific Medical Foundation, Sutter Medical Foundation, or Sutter Gould Medical Foundation. The Amended Complaint lacks any particularized allegations showing that any of these non-PAMF affiliates identified codes that they then failed to delete, or that any of them recklessly failed to identify codes that they should have deleted. These omissions are fatal—having chosen to differentiate her Complaint from the government’s based on a theory that fraud occurred at non-PAMF affiliates, Relator must plead particularized facts suggesting fraud at those affiliates.

United States ex rel. Duxbury v. Ortho Biotech Prods., L.P., 579 F.3d 13 (1st Cir. 2009) helps illustrate the shortcomings in Relator’s Amended Complaint. In *Duxbury*, the relator alleged that the defendant drug maker violated the False Claims Act by providing kickbacks to eight different healthcare providers that resulted in the submission of false claims. *Id.* at 30-31. The relator identified individuals at each of the eight providers, the specific illegal kickbacks at issue at each provider, and provided information regarding the amounts of the false claims by the providers. *See, e.g., id.* at 30 (quoting Relator’s Am. Compl. ¶ 211d) (“In 1997-98 Western Washington Cancer Treatment Center in Olympia, Washington received more than \$5,000 of free commercially packaged Procrit from Defendant under the direction of Robert Ashe so that Western Washington could submit the free product for reimbursement to Medicare under the false and fraudulent certification that the provider had paid for the product.”). The First Circuit, noting that it was “a close call,” concluded that the allegations satisfied Rule 9(b). *Id.* at 30. The court explained that even though the relator “alleged the submission of false claims across a large cross-section of providers” he adequately supported these allegations by identifying “the who, what, where, and when of the allegedly false or fraudulent representation . . . as to each of the eight medical providers[.]” *Id.* (emphasis added).

Relator’s Amended Complaint here is a far cry from the “close call” in *Duxbury*. It contains no particularized allegations of fraudulent activity at the non-PAMF affiliates, such as details of the individuals involved at each affiliate, the basis upon which to allege that coding at

1 each affiliate was “false,” or estimates of the value of false claims at each affiliate. For a
 2 Complaint purporting to allege fraud throughout Sutter’s “network of affiliates,” Relator has
 3 remarkably little to say about what was actually taking place at any non-PAMF affiliate.

4 In arguing that her allegations are sufficient, Relator relies extensively on allegations of
 5 audits that turned up unsupported codes at PAMF and Sutter Gould, Am. Compl. ¶ 100, and
 6 allegations that Sutter increased its average risk adjustment scores “across all affiliates,” *id.* ¶ 85.
 7 None of those allegations indicates fraud. At most, Relator’s allegations suggest a “mere
 8 opportunity” for fraud at the non-PAMF affiliates, which does not suffice under Rule 9(b).
 9 *Foglia v. Renal Ventures Mgmt., LLC*, 754 F.3d 153, 158 (3d Cir. 2014). And in terms of the
 10 required particularity, the allegations actually *undermine* Relator’s fraud claims. Relator
 11 specifically acknowledges Sutter’s various audits, the deletion of unsupported diagnosis codes
 12 following those audits, and the return of payments to the government for improper coding at the
 13 non-PAMF affiliates. Am. Compl. ¶ 99 (explaining the deletion of “thousands of unsupported
 14 diagnosis codes” found in the Peak Audit and RADV audit); *id.* ¶ 7 (“Sutter refunded CMS \$30
 15 million in overpayments for the improper coding at Sutter affiliates other than PAMF.”). These
 16 allegations are obviously *not* a particularized allegation that Sutter identified unsupported codes
 17 and then failed to return the associated payments. Indeed, they show exactly the opposite. And
 18 the very fact that Relator is relying on audits at non-PAMF affiliates that resulted in those
 19 affiliates voluntarily returning payments to the government indicates that Relator cannot offer
 20 any particularized allegations showing that such codes were identified and then not deleted.
 21 Relator is merely speculating, making allegations of fraud at affiliates to which she had no
 22 connection in the hope of a fortuitous recovery. Rule 9(b) is intended to prevent exactly that.
 23 *See United States ex rel. Swoben v. United Healthcare Ins. Co.*, 848 F.3d 1161, 1180 (9th Cir.
 24 2016) (“mere conclusory allegations of fraud are insufficient”).²

25
 26 ² Relator’s opposition (at 22) also overstates the allegations set forth in paragraph 100 of her
 27 Complaint regarding the Delete Project. Contrary to Relator’s argument, paragraph 100 does not
 28 specifically allege that the Delete Project found unsupported diagnosis codes at Sutter Gould.
 Instead, the Complaint alleges in two separate sentences that Relator was aware that the “Delete
 Project” and another audit were ongoing at PAMF and Sutter Gould *while she was at PAMF*, and
 that the Delete Project found unsupported codes for 2012 dates of service. The only allegation
 specific to Sutter Gould is that the Delete Project audit took place there.

1 Relator’s risk adjustment allegations also are generalized, Sutter-wide claims that fail
 2 Rule 9(b). Am. Compl. ¶ 85 (alleging that “Sutter increased its average HCC by 21% across all
 3 affiliates” and “had a system-wide increase of 25% in its RAF score”). For one thing, Relator
 4 does not actually allege that the increased average was the result of increased scores at non-
 5 PAMF affiliates. Further, at bottom, Relator’s theory rests on the entirely speculative notion that
 6 the scores went up as a result of fraud rather than as a result of legitimate efforts to better
 7 document diagnoses. Without particularized allegations on such points, Relator has failed to
 8 adequately plead fraud at the non-PAMF affiliates. As another court confronted with similar
 9 claims recently held, there is nothing improper or fraudulent about attempting to do a better job
 10 capturing patient diagnoses. *United States ex rel. Integra Med Analytics, LLC v. Baylor Scott &*
 11 *White Health*, 2019 WL 3713756, at *5 (W.D. Tex. Aug. 5, 2019).

12 **2. A “Collective Fraud” Theory Does Not Relieve Relator of Complying**
 13 **with Rule 9(b)**

14 Relator attempts to get around her lack of particularized allegations of fraud at the non-
 15 PAMF affiliates by arguing that “[a]ll the Sutter affiliates are subject to Sutter’s inflated RAF
 16 scheme in the same way.” Opp’n at 19. Relying on *United States ex rel. Silingo v. Wellpoint,*
 17 *Inc.*, 904 F.3d 667 (9th Cir. 2018), Relator contends that where a single member of an alleged
 18 fraudulent conspiracy acts as the “hub” (here, Sutter), the “parallel actions of the ‘spokes’” (here,
 19 the non-PAMF affiliates) can be addressed by “collective allegations.” Opp’n at 20.

20 Relator’s reliance on *Silingo* is misplaced. In *Silingo*, the defendant “spokes” (Medicare
 21 Advantage organizations) were found to have engaged in the same fraudulent scheme with a
 22 contractor “hub,” namely by retaining the “hub” to fraudulently increase capitation payments.
 23 *Id.* at 674, 678. The relator in *Silingo* pleaded specifically how the MA organization “spokes”
 24 engaged in the allegedly fraudulent scheme, for example by accepting health assessment reports
 25 and risk adjustment data from the “hub” that they knew contained fraudulent diagnosis codes.
 26 The court held that because each of the “spokes” was alleged to have participated in, and
 27 contributed to, the hub’s fraud in precisely the same way, the relator could impute the
 28

1 specifically pled allegations to each of the MA organizations. *Id.* at 678. There was no dispute
2 that the key elements of the alleged fraud were pleaded with particularity.

3 The instant case is different. Here, unlike *Silingo*, the Amended Complaint does not
4 allege a central actor who generated unsupported diagnosis codes on behalf of “spokes” that
5 perpetrated a fraud in precisely the same way. Instead, the Amended Complaint alleges that one
6 Sutter affiliate (PAMF) knowingly or recklessly generated false claims, and then speculates that
7 others likely did so as well. This is not enough for a “collective allegations” theory under
8 *Silingo*, where the court found that the relator provided specific factual support regarding the
9 defendants’ contracts with the “hub” and rejected the argument “that the complaint provide[d]
10 inadequate detail of their submission of false claims.” *Id.* at 678. Under *Silingo*, then, collective
11 allegations may be used to attribute *particularized* allegations applicable to one actor to other
12 actors engaged in the same alleged fraud—it does not support Relator’s apparent view that
13 collective allegations can be a *substitute* for particularity. Here, without particular details of
14 fraud at the non-PAMF affiliates, Relator cannot rely on a “collective allegations” theory to
15 satisfy Rule 9(b). *See Swoben*, 848 F.3d at 1184 (“The flaw in [relator]’s allegations is not the
16 use of collective allegations, but the failure to allege particular details of the scheme. . . .”).

17 3. Relator’s Remaining Arguments Fail

18 Relator’s remaining arguments do not save her Complaint. Relator argues that the \$30
19 million settlement between Sutter, Sutter’s non-PAMF affiliates, and the government is evidence
20 of fraud. Opp’n at 21, 22. But it is clear from the settlement agreement itself that the \$30
21 million is evidence of Sutter and the non-PAMF affiliates *properly returning* funds that they
22 concluded may have been the result of overpayments. Even Relator characterizes the settlement
23 as a “refund of improper overpayments,” but argues that the refund only reflected “*some* of the
24 overpayments” obtained at the non-PAMF affiliates. Opp’n at 24. That allegation only
25 reinforces what is missing in the Amended Complaint. To allege wrongful retention of an
26 overpayment, a relator must allege that a defendant knowingly avoided or decreased “an
27 obligation to pay or transmit money or property to the Government.” 31 U.S.C. § 3729(a)(1)(G).
28 Therefore, if Relator wants to rely on the \$30 million refund of improper payments as evidence

1 of *fraud*, then she must allege with particularity that the non-PAMF affiliates had an “obligation”
 2 to refund more than the \$30 million in payments *already returned*. Relator has not done so, and
 3 so the settlement cannot be indicative of fraud. *See United States v. Mount Sinai Hosp.*, 2015
 4 WL 7076092, at *13 (S.D.N.Y. Nov. 9, 2015) (relators adequately alleged fraud based on
 5 overpayments where the defendants had a “duty” to return the overpayments, but failed to do so).

6 Finally, Relator contends that it is improper “to weigh potentially competing inferences”
 7 on whether Sutter’s efforts to increase risk adjustment scores at its affiliates “were pursued
 8 through illegitimate means rather than indisputably permissible means, such as training doctors
 9 to do a better job of accurately capturing diagnosis codes.” Opp’n at 23 (quoting MTD at 7).
 10 But on a motion to dismiss, “courts *must* . . . consider an ‘obvious alternative explanation’ for
 11 defendant’s behavior.” *Eclectic Props. East, LLC v. Marcus & Millichap Co.*, 751 F.3d 990, 996
 12 (9th Cir. 2014) (emphasis added). Here, the “obvious alternative explanation” is that the non-
 13 PAMF affiliates sought to maximize coding opportunities consistent with existing law governing
 14 Medicare diagnoses,³ and sought training materials and guidance from Relator to ensure their
 15 physicians did so appropriately. *See* Am. Compl. ¶ 114 (alleging that “Relator’s peers in Sutter’s
 16 other affiliates” asked for “materials to train their physicians” on coding); *id.* ¶ 66 (alleging that
 17 “Relator’s team at PAMF” provided training to “counterparts at other affiliates to facilitate
 18 proper training on” diagnostic coding). Therefore, Relator’s Amended Complaint at most asserts
 19 a “possible” theory of liability rather than a “plausible” entitlement to relief. Accordingly, it
 20 cannot survive dismissal. *Integra*, 2019 WL 3713756, at *5 (dismissing complaint where
 21 relator’s allegations were “equally consistent” with the conclusion that Defendants were properly
 22 taking advantage of coding opportunities to maximize Medicare reimbursement”).

23 **III. CONCLUSION**

24 For the foregoing reasons, and the reasons outlined in Defendants’ Motion to Dismiss,
 25 the Court should not permit Relator to expand the allegations in this case beyond the intervened
 26 Complaint and should therefore dismiss Relator’s Amended Complaint.

27 ³ CMS has indicated there is nothing “inappropriate, unethical, or otherwise wrong with hospitals
 28 taking full advantage of coding opportunities to maximize Medicare payment that is supported
 by documentation in the medical record.” 72 Fed. Reg. 47130, 47180 (Aug. 22, 2007).

1 DATED: September 30, 2019

By: /s/ Katherine A. Lauer

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

LATHAM & WATKINS LLP
Katherine A. Lauer (Bar No. 138010)
katherine.lauer@lw.com
Jason M. Ohta (Bar No. 211107)
jason.ohta@lw.com
Amy E. Hargreaves (Bar No. 266255)
amy.hargreaves@lw.com
12670 High Bluff Drive
San Diego, CA 92130
Telephone: (858) 523-5400
Facsimile: (858) 523-5450

Steven M. Bauer (Bar No. 135067)
steven.bauer@lw.com
505 Montgomery Street, Suite 2000
San Francisco, CA 94111
Telephone: (415) 391-0600
Facsimile: (415) 395-8095

*Attorneys for Defendants Sutter Health and
Palo Alto Medical Foundation*